Clinical Trials Using Baricitinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Baricitinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients with Moderate and Severe COVID-19
This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir / ritonavir, and / or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.
Location: 2 locations
Baricitinib for the Prevention of Graft Versus Host Disease in Patients with Hematological Malignancies after Peripheral Blood Donor Stem Cell Transplantation
This phase I trial studies how well baricitinib works in preventing graft versus host disease in patients with hematological malignancies (blood cancers) after undergoing a peripheral blood donor stem cell transplantation. One of the side effects of a stem cell transplant is the development of graft versus host disease (GVHD). GVHD occurs when some of the cells from the donor attack the recipient’s tissues, resulting in mild, moderate, or even life-threatening side effects to the recipient’s skin, stomach, intestine, and liver. Baricitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and prevent or lessen the effects of GVHD in patients with hematological malignancies.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Study of Baricitinib, a JAK1 / 2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Chronic graft versus host disease (cGVHD) can affect people who had a hematopoietic stem cell transplant using donor cells. It is often fatal. It is usually treated with high doses of steroids. But that helps only about half the people in the long term. Researchers want to see if a drug called baricitinib can help people with cGVHD that has not responded to therapy. The drug inhibits the proteins involved in communication in the immune system. These proteins may play a role in cGVHD and other inflammatory diseases. Objectives: To test the safety and effectiveness of baricitinib in people with cGVHD that has not responded to therapy. Eligibility: Adults 18 and older with cGVHD that has not responded to therapy. Design: Participants will be screened with a medical history, physical exam, and blood and urine tests. They will have lung and heart tests and chest scans. Baseline visit: Participants will have: Medical history Physical exam Blood tests Tests for infectious diseases Skin, eye, and teeth evaluations Rehabilitation and occupational medicine evaluations Photos of any lesions Gynecology evaluation (females) The study will occur in 28-day cycles. Participants will take the study drug by mouth every day for 3 cycles. Some will take it for 3 or 6 more cycles. Participants will have a few visits during each cycle. They will repeat some previous tests. They may also have scans and questionnaires. Participants will have a visit when they stop taking the drug and another 3 months later. They will repeat a few study tests. They will have follow-up calls for 2 years.
Location: National Institutes of Health Clinical Center, Bethesda, Maryland